在伊朗治疗状细胞病的Crizanlizumab的成本效益分析
Marzieh Nosrati1,2, Shadi Izadidehkordi2,3, Shekoufeh Nikfar1,2
1Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Iranian journal of medical sciences
|August 27, 2025
概括
在伊朗,克里桑利祖马布对状细胞病 (SCD) 的治疗不具有成本效益. 即使降低了20%的价格,它的高成本也超过了单一治疗和基尿素组合治疗的可接受门.
科学领域:
- 药物经济学
- 健康经济学
- 血液学
背景情况:
- 在全球范围内,状细胞疾病 (SCD) 的患病率正在增加.
- 由于高成本,在低收入和中等收入国家 (LMIC) 通常无法获得FDA批准的SCD新药.
- 克里桑利祖马布具有潜在的临床和经济效益,但其在伊朗的成本效益尚未研究.
研究的目的:
- 评估克里桑利祖马布在伊朗状细胞病 (SCD) 的成本效益.
- 将克里桑利祖马布单一治疗与安慰剂进行比较.
- 为了比较克里桑利祖马布与氨酸和单独氨酸的组合.
主要方法:
- 使用决策树模型和成本效益分析.
- 研究对象是伊朗的医疗保健系统.
- 来自SUSTAIN试验的数据提供了有效性,对药物成本进行了敏感性分析.
主要成果:
- 克里桑利祖马布与基尿素的增量成本效益比 (ICER) 为398,881美元,超过了伊朗的成本效益门.
- 克里桑利祖马布单一治疗也超过了临界值.
- 敏感性分析表明,降低20%的价格并不能使克里桑利祖马布具有成本效益.
结论:
- 克里桑利祖马布不是伊朗状细胞病 (SCD) 的经济有效治疗方法.
- 单疗法和基尿素组合疗法都不符合成本效益标准.
- 药品价格的高昂仍然是LMIC国家获得药品的重要障碍.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174


